Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25Kymera plans to initiate a KT-621 Phase 1b trial in atopic ...

Kymera Therapeutics (KYMR) announced its corporate goals for 2025, including anticipated progress on its clinical pipeline of immunology ...

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust ...

Public health advice for HMPV is similar to that for flu, said John Tregoning, professor in vaccine immunology at Imperial ...

Fresenius Kabi Canada proudly announces the recent Health Canada Notice of Compliance (NOC) for OtulfiTM, an ustekinumab biosimilar indicated for Crohn's disease, ulcerative colitis, plaque psoriasis ...

Scinai Immunotherapeutics Ltd. ("Scinai" or the "Company"), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and offering CDMO services through its ...

Northern provinces in China have been hit with a surge of HMPV infections in the last three weeks. This has forced the centre ...

Researchers developed AbMAP, a cutting-edge framework leveraging transfer learning to model antibody hypervariable regions, ...

The average Ebola case fatality rate is around 50%. Case fatality rates have varied from 25-90% in past outbreaks.

Iovance Biotherapeutics and Adaptimmune brought first-of-their-kind cell therapy cancer treatments to market. Others had to ...

Harry Feinstone Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health, about the declining vaccine rates across the nation. "There is a vocal ...

Regulatory T (T Reg) cells are essential for maintaining peripheral tolerance, preventing autoimmunity and limiting chronic inflammatory diseases. However, they also limit beneficial responses by ...